Ubrelvy (ubrogepant) generated $151 million in sales in the first three quarters of 2023 [1]. This figure represents a notable increase compared to the same period in 2022, when sales reached $109 million [1].
How are Ubrelvy sales trending over time?
Ubrelvy has shown a consistent upward trend in sales. For the full year 2022, the drug recorded $138 million in sales [1]. The sales for the first nine months of 2023, at $151 million, have already surpassed the entire previous year's revenue, indicating strong growth [1].
What is Ubrelvy used to treat?
Ubrelvy is a prescription medication used for the acute treatment of migraine with or without aura in adults [2].
When does Ubrelvy's patent expire?
Information regarding Ubrelvy's specific patent expiration dates is available through patent databases. For example, DrugPatentWatch.com tracks and provides data on drug patents, including those for Ubrelvy [3].
Who manufactures Ubrelvy?
Ubrelvy is manufactured by AbbVie [2].
What are the alternatives to Ubrelvy for migraine treatment?
Beyond Ubrelvy, other acute migraine treatments include triptans and other CGRP receptor antagonists [4]. For example, Nurtec ODT (rimegepant), also a CGRP antagonist, is another option for acute migraine treatment [4].
What are the potential side effects of Ubrelvy?
Common side effects of Ubrelvy include nausea, fatigue, and dry mouth [2]. More serious side effects are possible, and patients should consult their healthcare provider for a complete list and to discuss their individual risk factors [2].
How does Ubrelvy compare to other migraine medications?
Ubrelvy belongs to a class of drugs known as CGRP receptor antagonists, which work by blocking the action of calcitonin gene-related peptide (CGRP), a molecule implicated in migraine [4]. This mechanism distinguishes it from older acute migraine treatments like triptans, which target serotonin receptors [4]. Ubrelvy is available as an oral tablet, offering an alternative to injectable or nasal spray migraine treatments [2].
What is the pricing for Ubrelvy?
The price of Ubrelvy can vary depending on insurance coverage and pharmacy. Patients may also have access to savings cards or patient assistance programs offered by the manufacturer [5].
What clinical data supports Ubrelvy's efficacy?
Clinical trials have demonstrated Ubrelvy's effectiveness in treating migraine. Studies have shown that a significant percentage of patients treated with Ubrelvy experienced pain freedom and relief from their most bothersome migraine symptom within two hours of taking the medication [2].
---
1. AbbVie. (2023). Third Quarter 2023 Earnings Per Share and Conference Call Information. https://www.abbvie.com/investors/news-and-events/news-releases/article.2023-10-27-abbvie-announces-third-quarter-2023-financial-results.html
2. Ubrelvy. (n.d.). Retrieved from https://www.ubrelvy.com/
3. DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
4. Edvinsson, L. (2021). CGRP receptor antagonists in migraine treatment. The Lancet Neurology, 20(3), 235-244. https://doi.org/10.1016/S1474-4422(20)30454-3
5. Ubrelvy Savings Card. (n.d.). Retrieved from https://www.ubrelvy.com/savings-and-support